JP2015506704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506704A5 JP2015506704A5 JP2014555799A JP2014555799A JP2015506704A5 JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5 JP 2014555799 A JP2014555799 A JP 2014555799A JP 2014555799 A JP2014555799 A JP 2014555799A JP 2015506704 A5 JP2015506704 A5 JP 2015506704A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant adenovirus
- nucleic acid
- adenovirus
- heterologous nucleic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 56
- 230000002163 immunogen Effects 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 150000007523 nucleic acids Chemical group 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 11
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 10
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 10
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 10
- -1 IL13Rα Proteins 0.000 claims description 10
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 8
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims description 6
- 238000012737 microarray-based gene expression Methods 0.000 claims description 6
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 101150005585 E3 gene Proteins 0.000 claims description 4
- 241001135569 Human adenovirus 5 Species 0.000 claims description 4
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- APHFXDBDLKPMTA-UHFFFAOYSA-N 2-(3-decanoyl-4,5,7-trihydroxynaphthalen-2-yl)acetic acid Chemical compound CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 claims description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 102100027106 BRCA1-associated protein Human genes 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims description 2
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims description 2
- 108060000903 Beta-catenin Proteins 0.000 claims description 2
- 102000015735 Beta-catenin Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101150104494 CAV1 gene Proteins 0.000 claims description 2
- 101150012716 CDK1 gene Proteins 0.000 claims description 2
- 102000000905 Cadherin Human genes 0.000 claims description 2
- 108050007957 Cadherin Proteins 0.000 claims description 2
- 102100026548 Caspase-8 Human genes 0.000 claims description 2
- 108090000538 Caspase-8 Proteins 0.000 claims description 2
- 102000004225 Cathepsin B Human genes 0.000 claims description 2
- 108090000712 Cathepsin B Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100038281 Cytospin-A Human genes 0.000 claims description 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims description 2
- 102100024400 Diphthine methyltransferase Human genes 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 2
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 2
- 102100039717 G antigen 1 Human genes 0.000 claims description 2
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 102100034153 Golgin subfamily A member 6B Human genes 0.000 claims description 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 2
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims description 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101000984746 Homo sapiens BRCA1-associated protein Proteins 0.000 claims description 2
- 101000944524 Homo sapiens Bombesin receptor-activated protein C6orf89 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000884816 Homo sapiens Cytospin-A Proteins 0.000 claims description 2
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims description 2
- 101001053233 Homo sapiens Diphthine methyltransferase Proteins 0.000 claims description 2
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 claims description 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims description 2
- 101100449143 Homo sapiens GOLGA6B gene Proteins 0.000 claims description 2
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 2
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 claims description 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims description 2
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000979578 Homo sapiens NK-tumor recognition protein Proteins 0.000 claims description 2
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 claims description 2
- 101100029612 Homo sapiens PHF20 gene Proteins 0.000 claims description 2
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims description 2
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101000583459 Homo sapiens Progesterone-induced-blocking factor 1 Proteins 0.000 claims description 2
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 claims description 2
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 claims description 2
- 101000849300 Homo sapiens Ribosomal RNA processing protein 36 homolog Proteins 0.000 claims description 2
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 2
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 claims description 2
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 2
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims description 2
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 claims description 2
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 102000016776 Midkine Human genes 0.000 claims description 2
- 108010092801 Midkine Proteins 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 2
- 102100023384 NK-tumor recognition protein Human genes 0.000 claims description 2
- 102000008730 Nestin Human genes 0.000 claims description 2
- 108010088225 Nestin Proteins 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 102100033615 Nucleoprotein TPR Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 102100036878 PHD finger protein 20 Human genes 0.000 claims description 2
- 101150038998 PLAUR gene Proteins 0.000 claims description 2
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 2
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims description 2
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 102100031015 Progesterone-induced-blocking factor 1 Human genes 0.000 claims description 2
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 102100029831 Reticulon-4 Human genes 0.000 claims description 2
- 102100033981 Ribosomal RNA processing protein 36 homolog Human genes 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 101150006914 TRP1 gene Proteins 0.000 claims description 2
- 102100038808 Transcription factor SOX-10 Human genes 0.000 claims description 2
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 2
- 102100039094 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 2
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims description 2
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 claims description 2
- 210000005055 nestin Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims description 2
- 108010014186 ras Proteins Proteins 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594005P | 2012-02-02 | 2012-02-02 | |
| US61/594,005 | 2012-02-02 | ||
| PCT/US2013/024506 WO2013116778A2 (en) | 2012-02-02 | 2013-02-01 | Immunogenic adenovirus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Division JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506704A JP2015506704A (ja) | 2015-03-05 |
| JP2015506704A5 true JP2015506704A5 (enExample) | 2016-03-17 |
| JP6325459B2 JP6325459B2 (ja) | 2018-05-16 |
Family
ID=47714593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555799A Active JP6325459B2 (ja) | 2012-02-02 | 2013-02-01 | 腫瘍関連異種抗原を発現するアデノウイルス |
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076878A Withdrawn JP2018138033A (ja) | 2012-02-02 | 2018-04-12 | 腫瘍関連異種抗原を発現するアデノウイルス |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11155599B2 (enExample) |
| EP (1) | EP2809788B1 (enExample) |
| JP (2) | JP6325459B2 (enExample) |
| KR (1) | KR102100092B1 (enExample) |
| CN (2) | CN104271748B9 (enExample) |
| AU (1) | AU2013214776B2 (enExample) |
| BR (1) | BR112014019049A2 (enExample) |
| CA (1) | CA2863523A1 (enExample) |
| DK (1) | DK2809788T3 (enExample) |
| ES (1) | ES2759785T3 (enExample) |
| NZ (1) | NZ628213A (enExample) |
| SG (3) | SG10201913795TA (enExample) |
| WO (1) | WO2013116778A2 (enExample) |
| ZA (1) | ZA201405755B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| EP2806883B1 (en) | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| CA2931322A1 (en) * | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| CN104328140B (zh) * | 2014-10-08 | 2018-06-05 | 兰州大学 | 一种高嗜性膀胱癌靶向性肿瘤杀伤腺病毒 |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| CN104762269A (zh) * | 2015-03-18 | 2015-07-08 | 红土生物技术有限公司 | 一种增强肿瘤抗原免疫原性的新策略及其在肺癌免疫治疗中的应用 |
| EP3286213B1 (en) * | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| ES2987442T3 (es) * | 2015-05-04 | 2024-11-14 | Theriva Biologics S L | Adenovirus oncolíticos con mutaciones en epítopos de adenovirus inmunodominantes y su uso en el tratamiento del cáncer |
| CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
| WO2017112797A1 (en) | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| JP7015551B2 (ja) * | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CN105779480B (zh) * | 2016-03-24 | 2020-03-20 | 成都康景生物科技有限公司 | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 |
| CN117534735A (zh) * | 2016-03-31 | 2024-02-09 | 欧洲分子生物学实验室 | 腺病毒外壳蛋白衍生递送载体 |
| WO2017205875A1 (en) * | 2016-05-27 | 2017-11-30 | Dnatrix, Inc. | Adenovirus and immunomodulator combination therapy |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| KR20190098215A (ko) * | 2016-12-21 | 2019-08-21 | 멤젠 엘엘씨 | 무장된 복제-가능 종양 분해 아데노바이러스 |
| SG11201906973TA (en) * | 2017-01-30 | 2019-08-27 | Epicentrx Inc | Multiple transgene recombinant adenovirus |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| CN112004923A (zh) | 2017-11-22 | 2020-11-27 | 迈索布拉斯特国际有限公司 | 细胞组合物及治疗方法 |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2019237371A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 定点插入 ct1.1 基因的 cho 细胞株的构建方法及其用途 |
| CN109081873B (zh) * | 2018-08-10 | 2022-04-22 | 固安鼎泰海规生物科技有限公司 | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020259189A1 (zh) * | 2019-06-27 | 2020-12-30 | 北京太东生物科技有限公司 | Sox11作为精神分裂症诊断标记物的应用 |
| CA3149478A1 (en) | 2019-08-05 | 2021-02-11 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2021194183A1 (ko) * | 2020-03-25 | 2021-09-30 | ㈜큐리진 | 면역 회피성 항종양 아데노바이러스 |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN111850041A (zh) * | 2020-07-30 | 2020-10-30 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的含il12双顺反子的病毒构建体及其用途和构建方法 |
| CN115996735A (zh) | 2020-08-10 | 2023-04-21 | 迈索布拉斯特国际有限公司 | 细胞组合物和治疗方法 |
| EP4602078A2 (en) | 2022-10-11 | 2025-08-20 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| FI972225A7 (fi) | 1994-11-28 | 1997-07-16 | Genetic Therapy Inc | Vektorit kudosspesifistä replikaatiota varten |
| CA2218610A1 (en) | 1995-04-17 | 1996-10-24 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| JP2002514075A (ja) | 1997-03-03 | 2002-05-14 | セル ジェネシス，インコーポレイティド | 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法 |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| CA2351587A1 (en) | 1998-11-18 | 2000-05-25 | Canji, Inc. | Viral vectors with late transgene expression |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| AU767904B2 (en) | 1999-05-12 | 2003-11-27 | Uab Research Foundation, The | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| US6635476B1 (en) | 1999-10-15 | 2003-10-21 | Canji, Inc. | Targeted vectors |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| US20070134202A1 (en) | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| CN101607985B (zh) | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2407177A1 (en) | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
| EP2383577A1 (en) | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| EP2806883B1 (en) | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| ES2878549T3 (es) | 2013-06-18 | 2021-11-19 | Dnatrix Inc | Adenovirus oncolítico para su uso en el tratamiento del cáncer cerebral |
-
2013
- 2013-02-01 SG SG10201913795TA patent/SG10201913795TA/en unknown
- 2013-02-01 CN CN201380017639.4A patent/CN104271748B9/zh not_active Expired - Fee Related
- 2013-02-01 NZ NZ628213A patent/NZ628213A/en not_active IP Right Cessation
- 2013-02-01 SG SG10201606356YA patent/SG10201606356YA/en unknown
- 2013-02-01 WO PCT/US2013/024506 patent/WO2013116778A2/en not_active Ceased
- 2013-02-01 DK DK13704334T patent/DK2809788T3/da active
- 2013-02-01 US US14/375,842 patent/US11155599B2/en active Active
- 2013-02-01 BR BR112014019049A patent/BR112014019049A2/pt not_active Application Discontinuation
- 2013-02-01 KR KR1020147024570A patent/KR102100092B1/ko not_active Expired - Fee Related
- 2013-02-01 JP JP2014555799A patent/JP6325459B2/ja active Active
- 2013-02-01 CN CN201910116066.XA patent/CN110042086A/zh active Pending
- 2013-02-01 SG SG11201404495RA patent/SG11201404495RA/en unknown
- 2013-02-01 ES ES13704334T patent/ES2759785T3/es active Active
- 2013-02-01 EP EP13704334.5A patent/EP2809788B1/en active Active
- 2013-02-01 CA CA2863523A patent/CA2863523A1/en not_active Abandoned
- 2013-02-01 AU AU2013214776A patent/AU2013214776B2/en not_active Ceased
-
2014
- 2014-08-05 ZA ZA2014/05755A patent/ZA201405755B/en unknown
-
2018
- 2018-04-12 JP JP2018076878A patent/JP2018138033A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506704A5 (enExample) | ||
| JP2018519847A5 (enExample) | ||
| ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
| Vici et al. | Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies | |
| De Haan et al. | Viral gene delivery vectors: the next generation medicines for immune-related diseases | |
| Gil et al. | CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells | |
| Anderson et al. | Plasmid DNA and viral vector-based vaccines for the treatment of cancer | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| JP2016540505A5 (enExample) | ||
| Kim et al. | Poxviral vectors for cancer immunotherapy | |
| JP2025160281A (ja) | 個別化ワクチン | |
| Asad et al. | Viral gene therapy for breast cancer: progress and challenges | |
| Liu et al. | An oncolytic adenovirus encoding decorin and granulocyte macrophage colony stimulating factor inhibits tumor growth in a colorectal tumor model by targeting pro-tumorigenic signals and via immune activation | |
| JP2017501695A5 (enExample) | ||
| Biegert et al. | Current development in adenoviral vectors for cancer immunotherapy | |
| Chaurasiya et al. | Viroimmunotherapy for breast cancer: Promises, problems and future directions | |
| Kim et al. | Enhanced antitumor immunotherapeutic effect of B-cell-based vaccine transduced with modified adenoviral vector containing type 35 fiber structures | |
| RU2019132253A (ru) | Новая днк-вакцина, нацеленная на pd-l1, для иммунотерапии рака | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| Lundstrom | Alphaviruses in cancer therapy | |
| Osada et al. | Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| Guo et al. | Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model | |
| JP2020507332A5 (enExample) | ||
| Lundstrom | Semliki Forest virus-based immunotherapy for cancer |